SKILLMAN, N.J.--(BUSINESS WIRE)--4M Therapeutics Inc., an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative conditions, today announced the formation of its Clinical Advisory Board comprised of five physician scientists and leaders in the treatment and research of a variety of neuropsychiatric and neurodegenerative conditions.

新泽西州斯基尔曼（BUSINESS WIRE）--4M Therapeutics Inc.，一家开发神经精神病和神经退行性疾病治疗的早期生物技术公司，今天宣布成立其临床咨询委员会，由五名医师科学家和各种神经精神病和神经退行性疾病治疗和研究的领导者组成。

This group of experts join Dr. Maurizio Fava, the company’s clinical consultant, in providing invaluable guidance and insights to the 4M Therapeutics management team..

该专家组与该公司的临床顾问Maurizio Fava博士一道，为4M治疗管理团队提供了宝贵的指导和见解。。

“Our newly formed Clinical Advisory Board brings together pioneers from top institutions across the country dedicated to treating central nervous system disorders,” said Dr. Pablo Lapuerta, Chief Executive Officer and Co-Founder of 4M Therapeutics. “We continue to build a robust team that we believe will enable us to capitalize on the potential of our novel drugs to better address a growing need for safer and more effective therapies for the brain.

4M Therapeutics首席执行官兼联合创始人巴勃罗·拉普尔塔（PabloLapuerta）博士表示：“我们新成立的临床咨询委员会汇集了来自全国顶尖机构的先驱，致力于治疗中枢神经系统疾病。”。“我们继续建立一支强大的团队，我们相信这将使我们能够利用新药的潜力，更好地满足对大脑更安全和更有效治疗的日益增长的需求。

I would like to welcome each new member to 4M Therapeutics, and we look forward to leveraging their expertise and decades of experience to advance our promising pipeline of compounds into the clinic.”.

我欢迎每一位新成员加入400万疗法，我们期待着利用他们的专业知识和数十年的经验，将我们有希望的化合物管道推进临床。”。

Andrew J. Cutler, M.D.

安德鲁·J·卡特勒，医学博士。

Dr. Cutler is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University and Chief Medical Officer of the Neuroscience Education Institute. He holds a BS in Biology from Haverford College, and obtained his medical degree from the University of Virginia School of Medicine, where he was elected into the Alpha Omega Alpha (AOA) honor medical society.

卡特勒博士是纽约州立大学上州立医科大学精神病学临床副教授，也是神经科学教育研究所的首席医学官。他拥有哈弗福德学院的生物学学士学位，并从弗吉尼亚大学医学院获得医学学位，在那里他被选入阿尔法-欧米茄-阿尔法（AOA）荣誉医学会。

Dr Cutler completed his medical internship and residencies in both Internal Medicine and Psychiatry at the University of Virginia Health Sciences Center, where he also did research training in dopamine receptor pharmacology. He is board certified in Internal Medicine by the American Board of Internal Medicine and in Psychiatry by the American Board of Psychiatry and Neurology.

卡特勒博士在弗吉尼亚大学健康科学中心完成了内科和精神病学的医学实习和住院治疗，并在那里进行了多巴胺受体药理学的研究培训。他获得了美国内科委员会的内科认证，以及美国精神病学和神经病学委员会的精神病学认证。

He is also a Certified Physician Investigator (CPI) from the Association of Clinical Research Professionals (ACRP)..

他还是临床研究专业人员协会（ACRP）的注册医师研究员（CPI）。。

Dr. Cutler has been conducting clinical research since 1993 and has been a Principal Investigator on over 400 clinical trials in a variety of CNS and medical indications, focusing on ADHD, bipolar disorder, depression and schizophrenia in children, adolescents and adults. He was an Assistant Professor of Psychiatry at the University of Chicago before moving to Florida and founding Florida Clinical Research Center (FCRC) in 1998.

自1993年以来，卡特勒博士一直在进行临床研究，并担任了400多项中枢神经系统和医学适应症临床试验的首席研究员，重点研究儿童、青少年和成人的多动症、躁郁症、抑郁症和精神分裂症。他是芝加哥大学精神病学助理教授，1998年移居佛罗里达并成立佛罗里达临床研究中心（FCRC）。

He sold FCRC to Meridien Research in 2016. He retired from Meridien as Executive Vice President and Chief Medical Officer in 2019. He has authored more than 150 peer-reviewed scientific articles and has presented more than 300 abstracts and posters at scientific meetings around the world. He is a peer reviewer for several prominent medical journals and has served on several editorial boards.

2016年，他将FCRC出售给了Meridien Research。2019年，他从Meridien退休，担任执行副总裁兼首席医疗官。他撰写了150多篇同行评议的科学文章，并在世界各地的科学会议上发表了300多篇摘要和海报。他是几家著名医学期刊的审稿人，并曾在多个编辑委员会任职。

He has chaired or attended over 250 medical and scientific advisory boards, delivered more than 3,000 national and international pharmaceutical promotional talks, and over 300 continuing medical education (CME) and Grand rounds presentations. He has participated in more than 50 national satellite TV medical education broadcasts and led 200-plus national medical web conferences.

他主持或出席了250多个医学和科学咨询委员会，发表了3000多篇国家和国际药物宣传演讲，以及300多篇继续医学教育（CME）和大回合演讲。他参加了50多个国家卫星电视医学教育广播节目，并领导了200多个国家医学网络会议。

Dr. Cutler consults with pharmaceutical and biotechnology companies and serves on the board of the Neuroscience Education Institute..

卡特勒博士为制药和生物技术公司提供咨询，并担任神经科学教育研究所董事会成员。。

Dr. Cutler is a member of the American Psychiatric Association (APA), the Florida Psychiatric Society (FPS) and the American Medical Association (AMA). He is honored to be a Fellow of both the APA and the Academy of Psychosomatic Medicine. He has received numerous professional honors and awards, including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the APA, the Outstanding Congressional Fellow Award from the 103rd US Congress, a citation from Florida Hospital for outstanding patient care, and the Distinguished Clinical Professional Award from the Central Florida Mental Health Association..

卡特勒博士是美国精神病学协会（APA）、佛罗里达精神病学会（FPS）和美国医学协会（AMA）的成员。他很荣幸成为APA和心身医学学会的研究员。他获得了许多专业荣誉和奖项，包括默克杰出医学奖学金奖、弗吉尼亚大学杰出患者护理骄傲奖、美国精神病学协会威廉·索拉姆奖、美国第103届国会杰出国会研究员奖、佛罗里达医院杰出患者护理奖以及佛罗里达州心理健康协会杰出临床专业奖。。

Dr. Maurizio Fava, M.D.

Maurizio Fava博士，医学博士。

Dr. Fava is Chair of the Department of Psychiatry/Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH), executive director of the Clinical Trials Network and Institute at MGH, and serves as the associate dean for clinical and translational research and the Slater Family Professor of Psychiatry at Harvard Medical School.

Fava博士是麻省总医院（MGH）精神病学系主任/精神病医生，MGH临床试验网络和研究所执行主任，并担任哈佛医学院临床和转化研究副院长和斯莱特家族精神病学教授。

Dr. Fava is a world leader in the field of depression and clinical psychopharmacology. He has edited eight books and authored or co-authored more than 900 original articles published in medical journals with international circulation which have been cited more than 100,000 times and with an h index greater than 150 on Google Scholar..

法瓦博士是抑郁症和临床精神药理学领域的世界领导者。他编辑了八本书，撰写或合著了900多篇原创文章，发表在国际发行的医学期刊上，被引用次数超过100000次，在Google Scholar上的h指数超过150。。

Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology at the same university. He then moved to the United States and completed residency training in psychiatry at MGH. He founded and was director of the hospital’s Depression Clinical and Research Program from 1990 until 2014.

法瓦博士从帕多瓦大学医学院获得医学学位，并在同一所大学完成了内分泌学住院医师培训。然后，他搬到了美国，并在MGH完成了精神病学住院医师培训。1990年至2014年，他创立并担任医院抑郁症临床和研究项目的主任。

Under Dr. Fava’s direction, the Depression Clinical and Research Program became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. In 2007, he also founded and is now the executive director of the MGH Psychiatry Clinical Trials Network and Institute, the first academic CRO specialized in the coordination of multi-center clinical trials in psychiatry..

在Fava博士的指导下，抑郁症临床与研究项目成为国内最受重视的抑郁症项目之一，是双向连接临床和研究工作的学术项目的典范。2007年，他还成立了MGH精神病学临床试验网络和研究所（MGH Psychiatry Clinical Trials Network and Institute）的执行主任，该研究所是第一个专门协调精神病学多中心临床试验的学术CRO。。

Dr. Fava has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $150 million. Dr. Fava’s prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, of the RAPID Network, the NIMH-funded series of studies of novel, rapidly-acting antidepressant therapies, and of the Clinical Coordinating Center of EPPIC-Net, the NINDS-funded network conducting proof-of-concept trials in pain.

Fava博士成功地从美国国立卫生研究院和其他来源获得了总金额超过1.5亿美元的首席或联合首席研究员资金。Fava博士在该领域的突出地位反映在他作为STAR*D（抑郁症领域有史以来规模最大的研究）的联合首席研究员，RAPID网络（NIMH资助的新型快速作用抗抑郁药治疗系列研究）和EPPIC网络临床协调中心（NINDS资助的进行疼痛概念验证试验的网络）的共同首席研究员。

Dr. Fava is a well-known national and international lecturer, having given more than 300 presentations at national and international meetings. He is the former President of the American Society of Clinical Psychopharmacology and, in 2023, Dr. Fava was elected to the National Academy of Medicine..

法瓦博士是国内外知名的讲师，曾在国内外会议上发表过300多篇演讲。他是美国临床心理药理学学会前主席，2023年，法瓦博士被选入美国国家医学院。。

Paul E. Keck, M.D.

保罗·E·凯克，医学博士。

Dr. Keck is Craig and Frances Lindner Professor of Psychiatry and Neuroscience at the University of Cincinnati (UC) College of Medicine. He is also President-CEO of the Lindner Center of HOPE, a state-of-the-science, UC-affiliated comprehensive mental health center in Mason, Ohio. He has been in the top 20 of the most cited scientists in the world, publishing in the fields of psychology and psychiatry, since 1996..

凯克博士是辛辛那提大学医学院精神病学和神经科学教授克雷格·林德纳和弗朗西斯·林德纳。他还是林德纳希望中心（LindnerCenter of HOPE）的总裁兼首席执行官，该中心是位于俄亥俄州梅森市的加州大学附属综合心理健康中心（National of the science）。自1996年以来，他一直是世界上被引用最多的科学家中的前20位，发表在心理学和精神病学领域。。

He is the author of over 375 scientific papers in leading medical journals. He has also contributed over 175 reviews and chapters to major psychiatric textbooks. Dr. Keck is the editor or author of 6 scientific books.

他在主要医学期刊上发表了375多篇科学论文。他还为主要精神病学教科书贡献了175多篇评论和章节。凯克博士是6本科学书籍的编辑或作者。

Dr. Keck is the recipient of numerous honors, including the Gerald Klerman Young Investigator Award from the National Depressive and Manic-Depressive Association (NDMDA); the Gerald Klerman Senior Investigator Award from the Depression & Bipolar Support Alliance (DBSA); the Exemplary Psychiatrist Award from the National Alliance of the Mentally Ill (NAMI); the Philip Isenberg Teaching Award from Harvard Medical School; two Communicator Awards for Continuing Medical Education; and two Golden Apple Teaching Awards from the University of Cincinnati College of Medicine.

凯克博士获得了许多荣誉，包括国家抑郁症和躁狂抑郁症协会（NDMDA）授予的杰拉尔德·克莱曼青年研究员奖；抑郁症和躁郁症支持联盟（DBSA）授予Gerald Klerman高级研究员奖；全国精神病联盟（NAMI）颁发的模范精神病学家奖；哈佛医学院菲利普·伊森伯格教学奖；两项继续医学教育传播奖；辛辛那提大学医学院授予两项金苹果教学奖。

He is listed as one of the Best Doctors in Cincinnati by Cincinnati Magazine, The Best Doctors in America, & Top Psychiatrists In America, & The World's Most Influential Scientific Minds by ScienceWatch..

他被《辛辛那提杂志》列为辛辛那提最佳医生之一，美国最佳医生，美国顶级精神病医生，科学观察（ScienceWatch）列为世界上最具影响力的科学头脑。。

A magna cum laude and Phi Beta Kappa graduate of Dartmouth College, Dr. Keck received his MD with honors from the Mount Sinai School of Medicine, New York, NY. He served his internship in Internal Medicine at the Beth Israel Medical Center in New York and completed his residency training in Psychiatry at Harvard Medical School and McLean Hospital, Belmont, MA.

凯克博士以优异成绩毕业于达特茅斯学院（Dartmouth College），获得纽约西奈山医学院（Mount Sinai School of Medicine）荣誉医学博士学位。他在纽约贝斯以色列医学中心（BethIsrael Medical Center）实习内科，并在哈佛医学院（Harvard Medical School）和马萨诸塞州贝尔蒙特的麦克莱恩医院（McLean Hospital）完成了精神病学住院医师培训。

Dr. Keck remained on faculty at McLean and Harvard before joining the Department of Psychiatry at the University of Cincinnati in 1991..

凯克博士在1991年加入辛辛那提大学精神病学系之前，一直在麦克莱恩和哈佛大学任教。。

Jonathan Meyer, M.D.

医学博士乔纳森·梅耶。

Dr. Meyer is a Voluntary Clinical Professor of Psychiatry at University of California, San Diego, and a Distinguished Life Fellow of the American Psychiatric Association. He is a graduate of Stanford University and Harvard Medical School, finished his adult psychiatry residency at LA County-USC Medical Center and completed fellowships there in Consultation/Liaison Psychiatry and Psychopharmacology Research.

迈耶博士是圣地亚哥加利福尼亚大学精神病学的自愿临床教授，也是美国精神病学协会杰出的终身研究员。他毕业于斯坦福大学和哈佛医学院，在南加州大学洛杉矶县医学中心完成了成人精神病学住院治疗，并在那里完成了咨询/联络精神病学和精神药理学研究的奖学金。

Dr. Meyer has teaching duties at UC San Diego and the Balboa Naval Medical Center in San Diego, and is a psychopharmacology consultant to the first episode psychosis program at Balboa Naval Medical Center in San Diego. Dr. Meyer has lectured and published extensively on psychopharmacology, and is the sole author of the chapter on the Pharmacotherapy of Psychosis and Mania for the last 3 editions of Goodman & Gilman's The Pharmacological Basis of Therapeutics.

Meyer博士在加州大学圣地亚哥分校和圣地亚哥巴尔博亚海军医学中心担任教学职务，并且是圣地亚哥巴尔博亚海军医学中心第一集精神病项目的精神药理学顾问。梅耶博士曾就精神药理学进行过广泛的演讲和出版，并且是古德曼和吉尔曼的《治疗学的药理学基础》最后三版《精神病和躁狂的药物治疗》一章的唯一作者。

Along with Dr. Stephen Stahl, he is co-author of the Clozapine Handbook published in 2019, The Clinical Use of Antipsychotic Plasma Levels released in 2021, and The Lithium Handbook published in 2023, all three by Cambridge University Press..

他与Stephen Stahl博士共同撰写了2019年出版的《氯氮平手册》、2021年出版的《抗精神病药物血浆水平的临床应用》和2023年出版的《锂手册》，这三本书均由剑桥大学出版社出版。。

Andrew Nierenberg, M.D.

安德鲁·尼伦伯格（AndrewNierenberg），医学博士。

Dr. Nierenberg is the Director of the Dauten Family Center for Bipolar Treatment Innovation, the Associate Director of the Depression Clinical and Research Program, and the Co-Director of the Center for Clinical Research Education at Massachusetts General Hospital. He developed an online research infrastructure called MoodNetwork to bring together patients, caregivers, and other stakeholders affected by mood disorders to better collect and understand patient data.

Nierenberg博士是Dauten家庭躁郁症治疗创新中心主任，抑郁症临床和研究计划副主任，以及马萨诸塞州总医院临床研究教育中心联合主任。他开发了一个名为MoodNetwork的在线研究基础设施，将患者、护理人员和其他受情绪障碍影响的利益相关者聚集在一起，以更好地收集和理解患者数据。

Dr. Nierenberg has published over 450 papers and has been listed in The Best Doctors in America for the treatment of mood and anxiety disorders in every edition since 1994. He attended medical school at the Albert Einstein College of Medicine and completed his residency at NYU/Bellevue Hospital Center..

尼伦伯格博士发表了450多篇论文，自1994年以来，他在每一版中都被列为美国治疗情绪和焦虑症的最佳医生。他就读于阿尔伯特·爱因斯坦医学院的医学院，并在纽约大学/贝尔维尤医院中心完成了住院治疗。。

Gary Sachs, M.D.

医学博士Gary Sachs。

Dr. Sachs is an internationally recognized expert clinician and clinical trialist with extensive experience in rater training and clinical trial methodologies for mood and anxiety disorder research. As Principal Investigator of the National Institute of Mental Health (NIHM) Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), Dr.

Sachs博士是国际公认的临床医生和临床试验专家，在情绪和焦虑症研究的评分员培训和临床试验方法方面拥有丰富经验。作为美国国家心理健康研究所（NIHM）躁郁症系统治疗增强计划（STEP-BD）的首席研究员。

Sachs led the largest treatment study ever conducted for bipolar disorder. He has been instrumental in developing practice guidelines and technology-based solutions for randomized controlled trials that identify correlates of high placebo response, improve signal detection and reduce the risk of failed trials..

Sachs领导了有史以来规模最大的躁郁症治疗研究。他一直致力于为随机对照试验制定实践指南和基于技术的解决方案，以确定高安慰剂反应的相关性，改善信号检测并降低试验失败的风险。。

Dr. Sachs is Clinical Vice President of Signant Health. He founded Concordant Rater Systems which was acquired by Signant Health in 2010. Dr. Sachs was also the founding director of the Bipolar Clinic and Research Program at Massachusetts General Hospital (MGH) and is Associate Clinical Professor of Psychiatry at the Harvard Medical School.

Sachs博士是Signant Health的临床副总裁。他创建了Concordant Rater Systems，该系统于2010年被Signant Health收购。Sachs博士也是马萨诸塞州总医院（MGH）躁郁症临床和研究项目的创始主任，也是哈佛医学院精神病学临床副教授。

After graduating from the University of Pennsylvania and the University of Maryland Medical School, he completed his residency at MGH. His areas of academic interest include clinical trial methodology, placebo response mitigation, psychopharmacology, patient centric outcome measures, bipolar mood disorder, and development of measure-based practice guidelines.

从宾夕法尼亚大学和马里兰大学医学院毕业后，他完成了在MGH的住院治疗。他的学术兴趣领域包括临床试验方法学，安慰剂缓解反应，精神药理学，以患者为中心的结果测量，双相情感障碍以及基于测量的实践指南的制定。

Dr. Sachs served on the board of directors for the Depression and Bipolar Support Alliance. Dr Sachs was president of the International Society for CNS Clinical Trial Methodology (ISCTM) 2022-2024. He has authored over 200 peer reviewed articles..

Sachs博士曾担任抑郁症和躁郁症支持联盟的董事会成员。Sachs博士是2022-2024年国际中枢神经系统临床试验方法学会（ISCTM）主席。他撰写了200多篇同行评议的文章。。

About 4M Therapeutics Inc.

约400万Therapeutics Inc。

4M Therapeutics Inc. (4MTx) is advancing treatments for neuropsychiatric and neurodegenerative diseases. The Company focuses on targets for a wide array of disorders and indications. 4MTx applies unique insights from its living human brain cell platform, which was developed through a collaboration between Harvard, MIT, and the University of Washington to identify and design more effective and safer therapeutics.

4M Therapeutics Inc.（4MTx）正在推进神经精神疾病和神经退行性疾病的治疗。该公司专注于针对各种疾病和适应症的目标。4MTx应用其活体人脑细胞平台的独特见解，该平台是通过哈佛大学、麻省理工学院和华盛顿大学的合作开发的，旨在确定和设计更有效和更安全的治疗方法。

The Company’s pipeline includes potential breakthrough treatments for bipolar mania, agitation in Alzheimer’s disease, neurodegeneration, and other CNS disorders. For more information, visit www.4mtx.net..

该公司的产品线包括对躁郁症、阿尔茨海默病躁动、神经退行性疾病和其他中枢神经系统疾病的潜在突破性治疗。有关更多信息，请访问www.4mtx.net。。